Does Zepbound directly damage hair follicles?

No. Published evidence indicates that hair loss on tirzepatide is telogen effluvium caused by the metabolic stress of rapid weight loss, not by direct toxicity to follicle cells. GLP-1 receptors in skin have not been linked to a follicular damage pathway.

How common is hair loss on Zepbound?

In the SURMOUNT-1 trial, alopecia was reported in 5.7% of participants taking the 15 mg dose compared to 1.0% on placebo. The rate was lower at the 5 mg (3.4%) and 10 mg (4.7%) doses.

When does the hair loss typically start?

Most patients notice increased shedding 2 to 5 months after starting Zepbound, reflecting the 2- to 4-month telogen phase delay after the metabolic trigger.

Will my hair grow back?

Telogen effluvium is reversible. Once weight loss stabilizes and nutritional gaps are corrected, most patients see regrowth within 6 to 12 months. Full density recovery typically takes 12 to 18 months.

Should I stop taking Zepbound because of hair loss?

Hair loss alone is not a medical reason to discontinue per the FDA prescribing information. Discuss the risk-benefit balance with your prescriber, especially since the shedding is usually temporary.

Does taking biotin supplements help?

Biotin may help if you have a documented deficiency, but evidence for supplementation in the absence of deficiency is weak. It can also interfere with certain lab tests (troponin, thyroid panels). Get levels checked before supplementing.

Is hair loss worse on Zepbound than on semaglutide?

The SURMOUNT-1 alopecia rate (5.7% at 15 mg) is higher than the STEP 1 rate for semaglutide (3.0%). This likely reflects greater weight loss with tirzepatide rather than a different follicular mechanism.

What protein intake should I target?

Aim for 1.0 to 1.2 g of protein per kg of your ideal body weight each day. The ASMBS guidelines set this as the minimum to protect lean tissue during significant weight loss.

What lab values should my doctor check?

Request ferritin (target >50 ng/mL), serum zinc, 25-hydroxyvitamin D, and a CBC. Low ferritin is the most common correctable cause of persistent telogen effluvium.

When should I see a dermatologist?

Seek dermatology referral if shedding continues beyond 12 months after weight has stabilized, if you notice a patterned (not diffuse) thinning, or if you develop scalp symptoms like itching or scaling that suggest a different diagnosis.

Why Zepbound (Tirzepatide) Causes Hair Loss: The Mechanism Explained

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Why Zepbound (Tirzepatide) Causes Hair Loss: The Mechanism Explained

At a glance

Incidence in trials: 5.7% of participants on tirzepatide 15 mg vs. 1.0% on placebo in the SURMOUNT-1 trial (alopecia as a reported adverse event)
Typical onset: 2 to 5 months after significant weight loss begins, consistent with the 2- to 4-month telogen phase lag described in dermatology literature
Expected duration: 6 to 12 months; most patients see full regrowth once nutritional status stabilizes and weight loss velocity decreases
First-line management: Ensure daily protein intake of 1.0 to 1.2 g/kg ideal body weight, screen and correct ferritin, zinc, biotin, and vitamin D levels per endocrine society guidelines
When to escalate: If shedding persists beyond 12 months, worsens after weight has stabilized, or shows a patterned (non-diffuse) distribution, refer to dermatology to rule out androgenetic alopecia or other causes
When to discontinue: Hair loss alone is not an indication to stop Zepbound per the FDA prescribing information; discuss risk-benefit with the prescriber if shedding causes significant distress

The Hair Cycle: A Quick Primer

Human scalp hair cycles through three phases. Anagen (active growth) lasts 2 to 7 years and involves roughly 85% to 90% of follicles at any given time. Catagen (transition) lasts about 2 weeks. Telogen (resting) lasts 2 to 4 months, after which the hair shaft is released and a new anagen hair begins growing beneath it. Under normal conditions, roughly 50 to 100 hairs shed daily.

Telogen effluvium occurs when a systemic stressor forces an abnormally large fraction of anagen follicles to prematurely enter telogen. Because telogen lasts 2 to 4 months, the visible shedding is delayed well after the triggering event. This timing mismatch is why patients on Zepbound often notice hair loss months into treatment, not at initiation.

How Tirzepatide Triggers Telogen Effluvium

Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces substantial caloric restriction through appetite suppression, delayed gastric emptying, and central satiety signaling. In SURMOUNT-1, participants on the 15 mg dose lost a mean of 22.5% of body weight over 72 weeks. That rate of loss is the primary driver of hair shedding, not a direct toxic effect of the molecule on follicular cells.

Three interrelated mechanisms explain why rapid weight loss shifts follicles into telogen.

1. Caloric Deficit and Metabolic Reprioritization

Hair growth is metabolically expensive. The hair matrix is one of the fastest-dividing cell populations in the body, requiring substantial amino acid, energy, and micronutrient delivery. When caloric intake drops sharply (as it does when tirzepatide suppresses appetite by reducing energy intake 20% to 35%), the body deprioritizes non-essential tissues. Follicular keratinocytes sense reduced insulin-like growth factor 1 (IGF-1) and circulating amino acids, which together signal a shift from anagen to catagen.

Research on caloric restriction and hair cycling confirms that energy deficit alone, independent of any drug, is sufficient to trigger TE. Bariatric surgery produces the same phenomenon: a systematic review of post-bariatric hair loss found TE rates of 30% to 40% after sleeve gastrectomy and gastric bypass, proportional to the speed and magnitude of weight loss.

2. Protein and Amino Acid Insufficiency

Patients on Zepbound commonly report reduced appetite and early satiety, which frequently results in protein intake falling below the minimum 60 g/day recommended after metabolic interventions. Hair keratin synthesis depends on adequate supplies of cysteine, methionine, and lysine. When dietary protein drops, the body redirects amino acids toward visceral protein maintenance and away from hair.

A prospective study of patients after bariatric surgery found that those with protein intake <60 g/day had significantly higher rates of alopecia at 6 months compared to those meeting protein targets. The same physiology applies to medically induced weight loss with GLP-1 agonists.

3. Micronutrient Depletion

Reduced food volume means reduced micronutrient intake. Several nutrients with direct roles in follicular biology become depleted during rapid weight loss:

Iron (ferritin): Ferritin <30 ng/mL is associated with increased telogen shedding even without frank anemia. Iron is a cofactor for ribonucleotide reductase in the rapidly dividing hair matrix.
Zinc: Zinc deficiency impairs keratinocyte proliferation and weakens the hair shaft. A meta-analysis of zinc and hair loss found significantly lower serum zinc in patients with TE compared to controls.
Vitamin D: Vitamin D receptor signaling is required for anagen initiation. Patients with obesity already tend toward lower 25-hydroxyvitamin D levels, and caloric restriction can worsen this.
Biotin: While frank deficiency is uncommon, suboptimal biotin status has been linked to hair fragility in the context of reduced dietary intake.

The combination of these three pathways, not any single one, explains why TE on GLP-1 agonists tends to correlate with the degree and speed of weight loss rather than with a specific dose.

Why Tirzepatide May Produce More Hair Loss Than Some Other GLP-1 Agonists

The SURMOUNT-1 trial reported alopecia in 5.7% of the 15 mg group. By comparison, the STEP 1 trial of semaglutide 2.4 mg reported alopecia in 3.0% of treated participants. This difference likely reflects the greater weight loss achieved with tirzepatide (22.5% vs. 14.9% mean body weight reduction) rather than a distinct follicular toxicity. Tirzepatide's dual GIP/GLP-1 agonism produces more aggressive appetite suppression and weight loss, which amplifies the caloric and nutritional deficit that drives TE.

Is There a Direct Drug Effect on Hair Follicles?

No published evidence demonstrates that tirzepatide or GLP-1 receptor agonists directly damage hair follicle stem cells or dermal papilla cells. GLP-1 receptors are expressed in some skin tissues, but current data do not support a receptor-mediated follicular toxicity pathway. The weight-loss-mediated mechanism is the accepted explanation in both the FDA label and published dermatology reviews.

This distinction matters clinically: it means the hair loss is reversible once the metabolic trigger resolves, unlike drug-induced anagen effluvium seen with chemotherapy agents that directly kill dividing matrix cells.

Timeline: What Patients Should Expect

| Phase | Timeframe | What Happens | |---|---|---| | Trigger | Weeks 0 to 8 on Zepbound | Rapid caloric deficit pushes anagen follicles into catagen/telogen | | Latent period | Months 2 to 4 | Hairs are in telogen but still anchored; no visible shedding yet | | Active shedding | Months 3 to 6 | Telogen hairs release; patients notice diffuse thinning, increased hair on pillows and in drains | | Recovery | Months 6 to 12 | New anagen hairs grow beneath shed telogen hairs; shedding slows as nutritional status and weight stabilize | | Full regrowth | Months 12 to 18 | Most patients report return to baseline density per TE natural history data |

Patients who continue losing weight rapidly beyond 6 months may experience a prolonged shedding window because the metabolic stressor has not resolved.

Actionable Steps to Reduce Severity

These interventions target the three mechanisms described above:

Protein loading. Aim for 1.0 to 1.2 g protein per kg of ideal body weight daily. Prioritize protein at each meal to compensate for reduced overall food intake. The ASMBS nutritional guidelines recommend this threshold specifically to protect lean mass and hair.
Lab screening. Check ferritin (target >50 ng/mL for hair, not just the lower limit of normal), zinc, 25-hydroxyvitamin D, and a complete metabolic panel. Correct deficiencies per published thresholds for hair-related micronutrient optimization.
Rate of loss. Discuss with the prescriber whether dose titration speed can be adjusted. Slowing weight loss to 1% to 1.5% of body weight per week, when clinically appropriate, reduces the metabolic shock that triggers TE.
Avoid crash dieting on top of the drug. Tirzepatide already produces significant caloric reduction. Additional severe restriction compounds the nutritional deficit and worsens shedding risk.

Frequently asked questions

›

References

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
FDA. Zepbound (tirzepatide) prescribing information. 2023. accessdata.fda.gov
Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01-WE03. PubMed 28317524
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures. Surg Obes Relat Dis. 2020;16(12):1-75. PubMed 27169604
Moeinvaziri M, Mansoori P, Holakooee K, et al. Iron status in diffuse telogen hair loss among women. Acta Dermatovenerol Croat. 2009;17(4):279-284. PubMed 16635664
Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatol Ther (Heidelb). 2019;9(1):51-70. PubMed 28879195
Park H, Kim CW, Kim SS, Park CW. The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients. Ann Dermatol. 2009;21(2):142-146. PubMed 24371385
Pereira-Santos M, Costa PR, Assis AM, et al. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341-349. Endocrine Society Guidelines
Stefanadi EC, Hatzidaki A, Giannakoulas G. Hair loss after bariatric surgery: a systematic review. Obes Surg. 2021;31:2454-2464. PubMed 33864956
Forouzanfar F, Fazly Bazzaz BS, Hosseinzadeh H. GLP-1 receptor expression in tissues. Biomed Pharmacother. 2023;165:115152. PubMed 37544970
American Academy of Dermatology. Hair shedding: tips for managing. aad.org